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A B S T R A C T
Mucopolysaccharidosis type II (MPS II - Hunter syndrome) is an X-linked lysosomal storage disorder caused by a
deficiency in the enzyme iduronate-2 sulfatase (I2S), leading to the accumulation of the glycosaminoglycans,
affecting multiple organs and systems. Enzyme replacement therapy does not cross the blood brain barrier,
limiting results in neurological forms of the disease. Another option of treatment for severe MPS, hematopoietic
stem cell transplantation (HSCT) has become the treatment of choice for the severe form of MPS type I, since it
can preserve neurocognition when performed early in the course of the disease. To date, only few studies have
examined the long-term outcomes of HSCT in patients with MPS II. We describe the seven-year follow-up of a
prenatally diagnosed MPS II boy with positive family history of severe MPS form, submitted to HSCT with
umbilical cord blood cells at 70 days of age. Engraftment after 30 days revealed mixed chimerism with 79%
donor cells; after 7 years engraftment remains at 80%. I2S activity 30 days post-transplant was low in plasma
and normal in leukocytes and the same pattern is observed to date. At age 7 years growth charts are normal and
he is very healthy, although mild signs of dysostosis multiplex are present, as well as hearing loss. The neu-
ropsychological evaluation (Wechsler Intelligence Scale for Children - Fourth Edition - WISC-IV), disclosed an IQ
of 47. Despite this low measured IQ, the patient continues to show improvements in cognitive, language and
motor skills, being quite functional. We believe that HSCT is a therapeutic option for MPS II patients with the
severe phenotype, as it could preserve neurocognition or even halt neurodegeneration, provided strict selection
criteria are followed.
1. Introduction
Mucopolysaccharidosis type II (MPS II, Hunter syndrome, OMIM
309900) is an X-linked lysosomal storage disorder caused by a defi-
ciency in the enzyme iduronate-2 sulfatase (I2S), leading to the accu-
mulation of the glycosaminoglycans (GAGs) dermatan sulfate and he-
paran sulfate [1]. The excessive storage of these GAGs both
intracellularly and extracellularly leads to the clinical features of the
disease.
MPS II affects multiple organs and systems with a variable age of
onset of signs and symptoms. Two clinical presentations of Hunter
syndrome have been reported, the mild, or attenuated, and the severe
forms. The severe phenotype, with primary neural parenchymal disease
is referred as neuronopathic MPS II and the mild phenotype, without
neural parenchymal involvement, as nonneuronopathic MPS II. The
distinguishing factor between the 2 forms is the presence, or absence, of
progressive intellectual deterioration. Both phenotypes exhibit cardi-
orespiratory and skeletal disease [2].
Historically, the management of Hunter syndrome was directed to
the specific disease symptoms and complications regardless the phe-
notype. In 2006, recombinant human I2S (idursulfase, Elaprase®, Shire
Human Genetics Therapies, Inc., Cambridge, MA, USA) was approved
for the treatment of Hunter syndrome in the United States, followed by
approval in many other countries [3]. The drug showed to improve
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many of the somatic manifestations, but since idursulfase is not pre-
dicted to cross the blood-brain barrier, the treatment cannot alter the
cognitive deterioration associated with the disease in patients with
severe MPS II [4,5].
Hematopoietic stem cell transplantation (HSCT) has become the
treatment of choice for the severe form of mucopolysaccharidosis type I
(Hurler syndrome) since it can preserve neurocognition when per-
formed early in the course of the disease [6–10]. HSCT has also been
performed in other MPS (non-MPS I), although often only evaluated as
part of a larger heterogeneous cohort of transplanted patients with
multiple metabolic diseases or as few case reports and with variable
results [11–13]. Compared to Hurler syndrome, the overall experience
in the use of HSCT for treatment of other MPSs (II, III, IV, VI and VII) is
very limited. Nevertheless, the scientific basis for effectiveness of HSCT
across the MPS spectrum remains the same: donor-derived cells would
secrete the deficient enzyme, which would be recaptured by sur-
rounding cells. The kinetics of cellular migration, differentiation, dis-
tribution and effective enzyme delivery, however, may differ among
MPS subtypes.
The majority of clinical experience of HSCT in MPS II patients
comes from observations of case studies. To date, only few authors have
examined the long-term outcomes of HSCT in groups of patients with
MPS II. In these studies, HSCT was found to increase or normalize I2S
activity in leukocytes, but not in serum, and was associated with de-
creased or normalized urinary GAG excretion. In 2009, a French report
on 8 boys with Hunter syndrome treated with BMT at 3 to 16 years and
followed for 7 to 17 years showed an excellent survival rate, stabiliza-
tion of cardiovascular problems, resolution of hepatosplenomegaly,
improvement in joint stiffness, arrested progression of perceptual
hearing defect and improvement in transmission hearing defects.
Improvements in neuropsychological function, however, were variable
and appeared to be related to disease severity at transplant [14]. Lack
of neurologic improvement was also described in 3 BMT recipients in a
1999 report with ages varying from 10 months to 5 years [15]. In a
recent report of the China Children Transplant Group including 34 MPS
children who underwent HSCT (12 MPS II), patients both with MPS I
and II aged 2 to 6 years at transplant showed some improvements in
motor and speech skills, suggesting that HSCT was also beneficial in
improving mental development in MPS II patients [16].
Although benefits have been observed regarding the somatic fea-
tures of the disease, the role of HSCT in MPS II remains controversial
because of lack of convincing evidence of neurocognitive benefit.
Despite the available reports, there are still no published data on HSCT
in very young, early stage, or asymptomatic children with the neuro-
nopathic MPS II phenotype.
2. Case report
We describe the seven years follow-up of a MPS II child submitted to
HSCT with umbilical cord blood cells at 70 days of age, preceded by
ERT. He was prenatally investigated due to positive family history, as
there were an older brother and an uncle diagnosed with Hunter syn-
drome, both with the severe phenotype. Undetectable iduronate-2-sul-
phatase (I2S) activity and the familial p.Arg88His mutation on exon 3
(p.R88H) were detected in fibroblasts of the amniotic fluid. This is a
missense mutation already reported and associated with the severe
phenotype of MPS II [17–19].
The patient was born at gestational age of 37 weeks and 2 days by
cesarean section due to nonprogression of vaginal delivery, weighing
3.320 g (50th centile), birth length of 51 cm (50th centile) and a head
circumference of 34 cm (50th centile).
Discrete lysosomal storage in endothelial cells and in pericytes was
observed in placental analysis by electronic microscopy (previously
described by [20]). Enzyme I2S activity re-confirmed the diagnosis of
MPS II in plasma [1,2 nmol/4 h/ml (ref = 122–463)] and leukocytes
[4,3 nmol/4 h/mg/protein (ref = 31–110)].
At birth, neurological examination showed generalized hyperexcit-
ability. Very discrete lumbar gibbus was observed and the X-ray survey
demonstrated discrete irregularity on the anterior face of vertebral
bodies L3, L4 and L5 (patient 1 in [21]).
Abdominal and cerebral ultrasound, echocardiogram, ophthal-
mology, audiology, pulmonary function, brain and spine MRI were
normal, except for a discrete enlargement of CSF space posterior to the
cerebellum. His neuropsychological evaluation with 1 month and
8 days of life using the Bayley Scales of Infant and Toddler
Development-Third Edition (Bayley-III) demonstrated a cognitive score
of 75, a language score of 74 and a motor score of 79.
At 19 days of life he presented fever and upper airways infection,
leading to hospital admission and intravenous antibiotic treatment for
10 days (6 days of ampicillin, 3 days of gentamicin, 3 days of cefo-
taxime and 4 days of ceftriaxone).
He received 6 weekly infusions of 0,5 mg/kg idursulfase from age
10 days until the transplantation, without any adverse reaction. The
response to ERT was evaluated with urinary GAG analysis. The baseline
GAG level at 10 days of age was 2000 mg/g creatinine (upper limit of
normal: 170 mg/g creatinine), which fell to 590 mg/g creatinine after
6infusions of ERT.
3. Transplant, engraftment and enzyme studies
HSCT with umbilical cord blood from HLA non-identical unrelated
donor (match 5/6) was performed at 70 days of age. HLA typing and
donor match were successful during pregnancy, and the match was
reconfirmed after birth. Conditioning regimen consisted of busulphan
320 mg/m2, cyclophosphamide 200 mg/kg and thymoglobulin 5 mg/
kg. He received a combination of cyclosporin and corticosteroid as
graft-versus-host disease prophylaxis.
Engraftment after 30 days revealed mixed chimerism with 79%
donor cells and after 7 years engraftment remains at 80%. IDS activity
30 days post-transplant was low in plasma (22 nmol/4 h/ml;
ref. = 122–463) and normal in leukocytes (49 nmol/4 h/mg protein;
ref. = 31–110); 270 days, 2, 3, 4, 5, 6 and 7 years after transplant the
same pattern was observed.
At 75 days post-transplant, routine laboratory tests revealed posi-
tive antibodies for cytomegalovirus. He began intravenous ganciclovir
10 mg/kg/day and continued the treatment for 6 months.
Urinary glycosaminoglycans (GAG) began to decrease during ERT
and reached the normal range 3 months post-transplant (135 mg/g
creatinine). At the moment, GAG levels are within the normal range for
age matched control (60 mg/g creatinine).
4. Follow-up and development
Motor milestones were all normal for age. His most recent motor
evaluation, with 7 years disclosed adequate muscle tone, strength and
joint range of motion within the normal range.
His speech development, however, has been slower. An auditory
evoked response test performed at 5 years was compatible with mod-
erate hearing loss. Hebegan to use a hearing device and started to speak
short phrases soon thereafter.
The patient always manifested increased general activity and as of
3 years of age he demonstrated aggressive behavior. Despite showing
benefit after introduction of the hearing aid and decrease of aggres-
siveness, hyperactive behavior is still present.
At age 7 years growth charts are normal; he weighs 39 kg (> 90th
centile), standing height is 129 cm (90th centile) and head cir-
cumference is 53 cm (75th centile). Motor development is also normal,
he has no skeletal problems, joint contractures or claw hands. He has
never had coarse facial features, corneal clouding or hepatosplenome-
galy. Physical examination discloses only short hands with stubby di-
gits, which is in agreement with previous reports of those transplanted
with the severe phenotype – Fig. 1 [22].
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Most recent evaluations performed at age of 7 years revealed
normal brain CT and normal upper airway fiberoptic findings.
Echocardiogram demonstrated completely normal cardiac function
with no signs of valvar dysfunction. MRI of the brain discloses mild
cerebellar hypoplasia, in accordance to the findings on the first exam in
the newborn period. MRI of the spine was normal and X-rays showed
very mild signs of dysostosis multiplex – Fig. 2.
Upper limbs somatosensory evoked potentials showed N20 cortical
waves with normal latencies after stimuli of ulnar nerves. Lower limbs
somatosensory evoked potentials showed P37 cortical waves with
prolonged latencies and prolonged central conduction time after stimuli
of posterior tibial nerves at 6.5 years. The neurophysiological findings
denote compromise of the sensory conduction in the posterior columns.
Such finding is in accordance to somatosensory abnormalities found in
MPS patients, although his findings are milder when compared to
nontransplanted patients [23].
Neuropsychological evaluation with 1 year and 11 months,
20 months after HSCT transplantation using the Bayley-III scale showed
cognitive score of 90, language score of 74 and motor score of 94. At
4 years and 3 months and at 6 years and 1 month, his IQ measured
through Wechsler Preschool and Primary Scale of Intelligence - Third
Edition (WPPSI-III Wechsler, 2002) was 57 and 50, respectively. In the
last neuropsychological evaluation with 7 years and 2 months using the
Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV), his
Fig. 1. Transplanted MPS II patient at age 7 years. (A): no joint
stiffness. (B) no MPS phenotype. (C) no claw hands.
Fig. 2. Mild Dysostosis Multiplex in the
transplanted MPS II boy. (A) Hands: shor-
tened and proximal pointing of metacarpals,
hypoplasia of carpals. (B) Pelvis: round iliac
wings and inferior iliac tapering (C) Long
bones: defect of linear growth with thick
shortened diaphyses. (D) Skull: thickened
calvaria. (E) Spine: inferiorly beaked ver-
tebrae and platyspondyly in lumbar spine.
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measured IQ was 47, being working memory and verbal comprehension
indexes his worst scores.
5. Discussion
HSCT has been performed in several lysosomal storage disorders
with different degrees of success [14]. In Hunter syndrome, the results
have been highly variable, with the majority of patients showing im-
provements of their somatic features and different responses regarding
the neuropsychological outcome [14,15,22,24,25].
When indicated in MPS (consensus for severe MPS I), HSCT should
be performed as early as possible as an attempt to avoid neurological
deterioration. The patient described here is one of the youngest MPS II
patients to have received HSCT so far; there is one patient reported to
have been transplanted at 1.5 month [26]. Our described patient had
the prediction of a severe phenotype proven both by the family history
and the genotype [17–19].
Since ERT significantly improves patient's pre-transplant condition
(improving respiratory and cardiac function), is well tolerated and does
not negatively influence engraftment, we chose to start ERT prior to
HSCT [9]. The initial idea was to continue ERT even after the trans-
plant, until blood enzyme activity was normal and he had a good en-
graftment. Since the patient was transplanted in another Brazilian state,
however, ERT was interrupted before the family travelled to the
transplant site due to reimbursement issues.
Literature data show that patients with MPS I have more hearing
improvement after HSCT in comparison to ERT [22,27]. The small
number of MPS II patients treated with HSCT makes it difficult to draw
any meaningful conclusion regarding hearing improvement in this po-
pulation. According to da Costa et al., HSCT at an early stage
(< 25 months) in MPS II patients does have a significant correlation to
hearing improvement [28]. Despite having been undertaken at an early
stage, HSCT seems not to have prevented the sensorineural hearing loss
in our patient. His poor behavior impeded a more complete audiologic
assessment, besides auditory brainstem responses (ABRs), so the con-
ductive component could not be tested. Nevertheless, he has never
presented any episode of otitis media, which is known to occur in 92%
of MPS II patients and is a major contributor to conductive hearing loss
[2].
The CMV infection after transplantation, although only positive
antigenemy was present and no clinical signs of infection were ob-
served, as well as medications used prior and post-transplant, may have
contributed to the hearing loss and confounded our data. Of note,
ganciclovir and gentamicin are well known ototoxic drugs [29].
Regarding the neuropsychological evaluations, the lower cognitive
score presented in patient's first evaluation at 38 days-old could have
been influenced by the time he spent hospitalized (at 19 days of age due
to upper airway infection), then improved in the second evaluation. It is
important to mention that the Bayley scale is not predictive in regards
of a child's performance as human development is complex and dy-
namic.
Unfortunately we had to use 3 different tests to evaluate patient's
DQ/IQ due to age limitation of the scales. Moreover, these scales are
only translated to Portuguese and not validated in the Brazilian popu-
lation, so cultural and socioeconomic biases could have contributed to
the low performance. Another weakness of the neuropsychological
evaluation was the use of WISC test, a heavily language based evalua-
tion, that may have been influenced by his hearing loss and resulted in
poor performance. It is worthwhile to mention that our patient has
never attended physical, occupational or language therapies, although
strongly recommended, which could have improved his performance in
the cognitive tests.
Literature shows that severe Hunter patients improve their cognitive
function until they reach a plateau at approximately 48 to 55 months of
age and thenceforth it declines rapidly [2]. Our patient is keeping a
relatively stable IQ, which implies he is gaining skills at an almost
normal rate. In fact, he is a very functional child who attends regular
school (although a bit delayed for chronological age), interacts well
with other children, practices sports, eats unaided and plays video-
game. In the Pediatric Evaluation of Disability inventory (PEDI), func-
tional skills section, he scored 156 out of 197, showing a quite good
functional performance or at least much better than expected for a boy
of his age with the neuronopathic MPS II phenotype. We have also
assessed the activities of daily living (ADL) through ADL questionnaire
for patients with Hunter syndrome designed by Tanjuakio [30]. In this
instrument he obtained a score of 43 out of a total of 60, which is
among the highest for patients with the severe phenotype.
When comparing him to the other MPS II relatives in the family (a
deceased older brother at age 12, who began ERT at the age of 6 years
and a deceased 20 year old severely bedridden uncle diagnosed at
8 years, who had never been treated with ERT), his is doing much
better. Table 1 and Figs. 3 and 4 show differences in development and
phenotype between the propositus and the other affected in the family.
In regards to transplant in diseases with neurologic progression, it
seems that if the procedure is performed very early in the disease
process, more neurocognitive benefits would occur. For the brain, it has
been observed that donor-derived macrophages cross the blood-brain
barrier with subsequent differentiation into microglia, secreting the
deficient enzyme for recapture by surrounding neurons. The timing of
migration to and engraftment of donor-derived microglial cells after
HSCT is not known, but probably, on the basis of clinical observation, it
takes months after hematologic engraftment. Thus, an explanation for
the failure of HSCT to prevent mental deterioration in certain patients
could be the slow pace of replacement of patient tissue macrophages
and microglia populations by donor hematopoietic cell progeny lim-
iting the success for rapidly progressive neurologic diseases ([31,32]).
It is important to point out that the majority of the available lit-
erature on HSCT in MPS II patients is outdated. There are only few case
reports, showing no rigid selection criteria of the candidates, who were
from different age groups and already presented signs of cerebral in-
volvement at the time of transplantation, reasons that may have in-
fluenced the unsuccessful outcomes of transplantation. After 2006, with
the approval of Elaprase®, ERT became the treatment of choice for
Hunter patients. Even though the intravenous therapy is known not to
cross the BBB, being unable to prevent neurodegeneration in the severe
form of MPS II, for some reason it seems that HSCT was discouraged
and no longer performed. We consider that HSCT for MPS II patients is
still an unexplored alternative which can bring more neurological
benefits than ERT.
Table 1







Diagnosis Pre-natal 4 years 8 years






Head support 2 months 4–5 months 6 months
Sat unaided 5 months 8–9 months 9 months
Babbled 5–6 months After 1 year 1 year and
6 months
Crawled 7 months 10 months 1 year




Toilet trained 4 years Never Never
Self-feeding 3 years Never Never
Shower unaided 5 years Never Never





Never 4 years 8 months
Stopped walking – 10 years 10 years
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It is also still worth mentioning that> 10 years ago HSCT in MPS
patients was limited by lack of donor availability, high rates of graft
failure and transplantation-related morbidity and mortality. Nowadays,
the observed high engrafted survival rates with reduced toxicity and
complications, due to the new transplant protocols and techniques
[6,16], along with superior metabolic correction compared with ERT
[13], all together with a more careful and restricted selection of pa-
tients, may enable the extension of HSCT indication for MPS II patients.
Whether transplantation prior to the onset of neurological symp-
toms would prevent a severe outcome has yet to be proven in patients
with MPS II. Longer follow-up and reports of further early transplanted
cases are still necessary. Noteworthy, our patient, instead of losing
cognitive skills as expected for a MPS II boy at his age, continues to
acquire cognitive, adaptative and language skills, although at a slower
rate when compared to unaffected children. This case is probably the
first long-term and detailed report to demonstrate that HSCT performed
very early in the course of the disease may be able to preserve cognition
as our patient shows a continuous gain in skills, albeit at a slower rate
than unaffected children.
6. Conclusions
We believe that HSCT is a therapeutic option for MPS II patients
with the severe phenotype, as it could preserve neurocognition or even
halt neurodegeneration, provided strict selection criteria are followed.
The new protocols and techniques of transplantation have made the
procedure more accessible and secure for the patients. HSCT could be
considered a more suitable option for the patient and family, as no
weekly lifelong infusions would be needed. Regarding public health
policy, we dare to consider it as an interesting treatment option, both
due to efficacy and to the lower overall therapy cost when compared to
ERT for life.
Competing interests
AL Barth has received educational travel grants and/or speaker
honoraria from Biomarin, Shire and Sanofi Genzyme; TSPC Magalhães
is currently an employee of Biomarin; R Giugliani has received in-
vestigator fees, speaker honoraria, and travel grants from Actelion,
Amicus, Armagen, Biomarin, Sanofi Genzyme, Shire and Ultragenyx;
DA Torres has received educational travel grants and/or speaker hon-
oraria from Biomarin and Shire; JC Llerena Jr. has received educational
travel grants and/or speaker honoraria from Biomarin, Shire and Sanofi
Genzyme, DDG Horovitz has received educational travel grants and/or
speaker honoraria from Biomarin, Shire, Sanofi Genzyme and
Ultragenyx; ABR Reis; MLC Oliveira; FB Scalco; NC Cavalcanti; DS
Fig. 3. Clinical phenotype of the propositus (A), his older
brother (B) and uncle (C) at age of 6 years. The propositus
at age 4 years and his brother at age 12 years (D).The
propositus at age 7 years and his uncle at age 20 years (E).
A.L. Barth et al. Molecular Genetics and Metabolism Reports 12 (2017) 62–68
66
Silva; AAP Costa and C Bonfim have no competing interests.
Acknowledgments
The authors thank Drs Maira Burin, Ida Schwartz, Sandra Leistner-
Segal, Guilherme Baldo, Rejane Gus Kessler and the Brazilian MPS
Network, all based at MGS/HCPA/UFRGS – Brazil, for the prenatal
diagnosis support, enzyme and molecular studies; Lisandro Lima
Ribeiro and Gisele Loth from BMT Unit/UFPR – Brazil, for the medical
support during HSCT.
References
[1] E.F. Neufeld, J. Muenzer, The Mucopolysaccharidoses, in: C.R. Scriver,
A.L. Beaudet, W.S. Sly, D. Valle (Eds.), The Metabolic and Molecular Bases of
Inherited Disease, 8th ed, McGrow-Hill, New York, 2001, pp. 3421–3452.
[2] J.B. Holt, M.D. Poe, M.L. Escolar, Natural progression of neurological disease in
mucopolisaccharidosis type II, Pediatrics 127 (2011) e1258–e1265.
[3] J. Muenzer, O. Bodamer, B. Burton, L. Clarke, et al., The role of enzyme replace-
ment therapy in severe Hunter syndrome – an expert panel consensus, Eur. J.
Pediatr. 171 (2012) 181–188.
[4] R.J. Boado, E.K. Hui, J.Z. Lu, R.K. Sumbria, W.M. Pardridge, Blood-brain barrier
molecular Trojan horse enables imaging of brain uptake of radioiodinated re-
combinant protein in the rhesus monkey, Bioconjug. Chem. 24 (2013) 1741–1749.
[5] C. Lampe, A.K. Bosserhoff, B.K. Burton, R. Giugliani, et al., Long-term experience
with enzyme replacement therapy (ERT) in MPS II patients with a severe pheno-
type: an international case, J. Inherit. Metab. Dis. 37 (2014) 823–829.
[6] M. Aldenhoven, R.F. Wynn, P.J. Orchard, A. O'Meara, et al., Long-term outcome of
Hurler syndrome patients after hematopoietic cell transplantation: an international
multicenter study, Blood 125 (2015) 2164–2172.
[7] A. Gosh, W. Miller, P.J. Orchard, S.A. Jones, et al., Enzyme replacement therapy
prior to hematopoietic stem cell transplantation in mucopolysaccharidosis type I:
10 year combined experience of 2 centers, Mol. Genet. Metab. 117 (2016) 373–377.
[8] M.D. Poe, S.L. Chagnon, M.L. Escolar, Early treatment is associated with improved
cognition in Hurler syndrome, Ann. Neurol. 76 (2014) 747–753.
[9] M.H. de Ru, J.J. Boelens, A.M. Das, S.A. Jones, et al., Enzyme replacement therapy
and/or hematopoietic stem cell transplantation at diagnosis in patients with mu-
copolysaccharidosis type I: results of a European consensus procedure, Orphanet J.
Rare Dis. 6 (2011) 55.
[10] J.E. Wraith, M. Beck, R. Lane, A. van der Ploeg, et al., Enzyme replacement therapy
in patients who have mucopolysaccharidosis I and are younger than 5 years: results
of a multinational study of recombinant human alpha-L-iduronidase (laronidase),
Pediatrics 120 (2007) e37–e46.
[11] C. Peters, C.G. Sterward, Hematopoietic cell transplantation for inherited metabolic
diseases: an overview of outcomes and practice guidelines, Bone Marrow
Transplant. 31 (2003) 229–239.
[12] V.K. Prasad, A. Mendizabal, S.H. Parikh, P. Szabolcs, et al., Unrelated donor um-
bilical cord blood transplantation for inherited metabolic disorders in 159 pediatric
patients from a single center: influence of cellular composition of the graft on
transplantation outcomes, Blood 112 (2008) 2979–2989.
[13] R.F. Wynn, J.E. Wraith, J. Mercer, et al., Improved metabolic correction in patients
with lysosomal storage disease treated with hematopoietic stem cell transplant
compared with enzyme replacement therapy, J. Pediatr. 154 (2009) 609–611.
Fig. 4. Propositus' uncle at 7 years. X-Ray images showing signs of
severe dysostosis multiplex in the hand (A) - proximal pointing of
metacarpals, shortened metacarpals and carpal hypoplasia - and
spine (B) - abnormal modeling and inferiorly beaked vertebrae.
Cranial computed tomography (C) and (D) showing enlargement
of the supratentorial ventricles and cortical atrophy, even after
shunting.
A.L. Barth et al. Molecular Genetics and Metabolism Reports 12 (2017) 62–68
67
[14] N. Guffon, Y. Bertrand, I. Forest, A. Fouilhoux, R. Froissart, Bone marrow trans-
plantation in children with Hunter syndrome: outcome after 7 to 17 years, J.
Pediatr. 154 (2009) 733–737.
[15] A. Vellodi, E. Young, A. Cooper, V. Lidchi, et al., Long-term follow-up following
bone marrow transplantation for Hunter disease, J. Inherit. Metab. Dis. 22 (1999)
638–648.
[16] J. Wang, Z. Luan, H. Jiang, J. Fang, et al., Allogeneic hematopoietic stem cell
transplantation in 34 pediatric cases of mucopolysaccharidosis – a 10-year report
from China children transplant group, Biol. Blood Marrow Transplant. 22 (2016)
2104–2108.
[17] A.C. Brusius-Facchin, I.V.D. Schwartz, C. Zimmer, M.G. Ribeiro, et al.,
Muchopolysaccharidosis type II: identification of 30 novel mutation among Latin
American patients, Mol. Genet. Metab. 111 (2014) 133–138.
[18] M.A.D. Chiong, D.M. Canson, M.A.R. Abacan, M.M.P. Baluyot, C.P. Cordero,
C.L.T. Silao, Clinical, biochemical and molecular characteristics of Filipino patients
with mucopolysaccharidosis type II – Hunter syndrome, Orphanet J. Rare Dis. 12
(2017) 7.
[19] R. Froissart, I.M. da Silva, I. Maire, Mucopolysaccharidosis type II: an update on
mutation spectrum, Acta Paediatr. 96 (2007) 71–77.
[20] G. Baldo, U. Matte, O. Artigalas, I.V. Schwartz, et al., Placenta analysis of prenatally
diagnosed patients reveals early GAG storage in mucopolysaccharidoses II and VI,
Mol. Genet. Metab. 103 (2011) 197–198.
[21] C. Lampe, A. Atherton, B.K. Burton, M. Descartes, et al., Enzyme replacement
therapy in mucopolysaccharidosis II patients under 1 year of age, JIMD Rep. 14
(2014) 99–113.
[22] G. Souillet, N. Guffon, I. Maire, M. Pujol, et al., Outcome of 27 patients with Hurler's
syndrome transplanted either from related or unrelated haematopoietic stem cell
sources, Bone Marrow Transplant. 31 (2003) 1105–1117.
[23] D.S. Silva, A.L. Barth, A.C. Esposito, A.A.P. Costa, et al., Neurophysiological
evaluation in cervical myelopathy in patients with mucopolysaccharidosis: the so-
matosensory and motor-evoked potentials, JIEMS 2 (2014) S25.
[24] E.J.R. McKinnis, S. Sulzbacher, J.C. Rutledge, J. Sanders, C.R. Scott, Bone marrow
transplantation in Hunter syndrome, J. Pediatr. 129 (1996) 145–148.
[25] A. Tanaka, T. Okuyama, Y. Suzuki, N. Sakai, et al., Long-term efficacy of hemato-
poietic stem cell transplantation on brain involvement in patients with mucopoly-
saccharidosis type II: a nationwide survey in Japan, Mol. Genet. Metab. 107 (2012)
513–520.
[26] M. Escolar, M. Poe, D. Rajan, P. Szabolcs, Longterm outcomes of patients receiving
umbilical blood stem cell transplantation for MPS II, Mol. Genet. Metab. 108 (2012)
S37–S38.
[27] B.C. Papsin, A. Vellodi, C.M. Bailey, P.C. Ratcliffe, S.E. Leighton, Otologic and
laryngologic manifestations of mucopolysaccharidosis after bone marrow trans-
plantation, Otolaryngol. Head Neck Surg. 118 (1998) 30–36.
[28] V. da Costa, G. O'Grady, L. Jackson, D. Kaylie, E. Raynor, Improvements in sen-
sorineural hearing loss after cord blood transplant in patients with mucopoly-
saccharidosis, Arch. Otolaryngol. Head Neck Surg. 138 (2012) 1071–1076.
[29] G. Cianfrone, D. Pentangelo, Mazzei F. CianfroneF, et al., Pharmacological drugs
inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated
guide, Eur. Rev. Med. Pharmacol. Sci. 15 (2011) 601–636.
[30] J. Tanjuakio, Y. Suzuki, P. Patel, E. Yasuda, et al., Activities of daily living in pa-
tients with Hunter syndrome: impact of enzyme replacement therapy and hema-
topoietic stem cell transplantation, Mol. Genet. Metab. 114 (2015) 161–169.
[31] M. Aldenhoven, J. Kurtzberger, Cord blood is the optimal graft source for the
treatment of pediatric patients with lysosomal storage diseases: clinical outcomes
and future directions, Cytotherapy 17 (2015) 765–774.
[32] R. Wynn, Stem cell transplantation in inherited metabolic disorders, Hematology
Am. Soc. Hematol. Educ. Program 2011 (2011) 285–291.
A.L. Barth et al. Molecular Genetics and Metabolism Reports 12 (2017) 62–68
68
